Precigen (PGEN) Return on Capital Employed (2013 - 2026)
Precigen's (PGEN) quarterly Return on Capital Employed came in at 74.55% in Q1 2026, up 4330.0% year-on-year from 1.68% in Q1 2025, and up 14.94% on a QoQ basis from 87.65% in Q4 2025.
Precigen (PGEN) Return on Capital Employed (2013 - 2026) Analysis & Trends
Precigen (PGEN) has 14 years of Return on Capital Employed data on file, last reported at 74.55% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 4330.0% year-over-year to 74.55% in Q1 2026; TTM through Mar 2026 was 74.55%, a 4330.0% increase from a year earlier, with the FY2025 full-year figure at 97.73%, up 890.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 74.55%, up from 87.65% in the prior quarter.
- Over the last five years, Return on Capital Employed for PGEN reached as high as 28.49% in Q1 2022 and fell as low as 246.47% in Q3 2024.
- Historically, Return on Capital Employed has averaged 88.61% across 5 years, with a median of 74.55% in 2026.
- Across the five-year window, Return on Capital Employed plunged 19393 bps in 2024 and jumped 13418 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 47.64% in 2022, then sank by 42 bps to 67.46% in 2023, then plunged by 116 bps to 145.42% in 2024, then jumped by 40 bps to 87.65% in 2025, then gained by 15 bps to 74.55% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 74.55% in Q1 2026, 87.65% in Q4 2025, and 112.29% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Precigen | 1.96 Bn | 1.96 Bn | 20.69 Mn | -74.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -74.55% |
| Dec 31, 2025 | -87.65% |
| Sep 30, 2025 | -112.29% |
| Jun 30, 2025 | -113.01% |
| Mar 31, 2025 | -117.85% |
| Dec 31, 2024 | -145.42% |
| Sep 30, 2024 | -246.47% |
| Jun 30, 2024 | -173.39% |
| Mar 31, 2024 | -88.19% |
| Dec 31, 2023 | -67.46% |
| Sep 30, 2023 | -52.54% |
| Jun 30, 2023 | -38.20% |
| Mar 31, 2023 | -42.33% |
| Dec 31, 2022 | -47.64% |
| Sep 30, 2022 | -40.89% |
| Jun 30, 2022 | -30.06% |
| Mar 31, 2022 | -28.49% |
| Dec 31, 2021 | -26.16% |
| Sep 30, 2021 | -27.89% |
| Jun 30, 2021 | -27.15% |